Literature DB >> 7628093

Interpretation of serial measurements of international normalized ratio for prothrombin times in monitoring oral anticoagulant therapy.

J F Lassen1, J Kjeldsen, S Antonsen, P Hyltoft Petersen, I Brandslund.   

Abstract

Despite careful monitoring of oral anticoagulant treatment (OAT), some international normalized ratio (INR) for prothrombin time values will fall outside the therapeutic range. Considerable changes in serial INR results from OAT patients may be caused by random fluctuation alone, and, for statistical reasons, a fraction of the INR values will fall outside therapeutic range and interfere with dose adjustments. On the basis of therapeutic intervals and statistical evaluation of reference changes, we suggest and discuss an alternative method for interpretation of serial INR measurements. Retrospective evaluation of serial measurements of INR from OAT patients revealed an "overshooting" phenomenon. When a dose was adjusted on the basis of insignificant change in INR value, the subsequent INR value generally fell in the opposite direction. If a further change of dose was initiated because of the new INR value, a similar course in the opposite direction was observed. This "ping-pong" effect renders patients in a fluctuating state of anticoagulation and may introduce increased risk of complications. The suggested method provides an objective criterion for dose adjustments in OAT, which should reduce patients' risk.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7628093

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  8 in total

1.  CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.

Authors:  Paulo Caleb Junior Lima Santos; Carla Luana Dinardo; Isolmar Tadeu Schettert; Renata Alonso Gadi Soares; Liz Kawabata-Yoshihara; Isabela Martins Bensenor; José Eduardo Krieger; Paulo Andrade Lotufo; Alexandre Costa Pereira
Journal:  Eur J Clin Pharmacol       Date:  2012-09-19       Impact factor: 2.953

2.  Interaction between acetaminophen and warfarin in adults receiving long-term oral anticoagulants: a randomized controlled trial.

Authors:  Qian Zhang; Claire Bal-dit-Sollier; Ludovic Drouet; Guy Simoneau; Jean-Claude Alvarez; Sandrine Pruvot; Romain Aubourg; Natacha Berge; Jean-Francois Bergmann; Stéphane Mouly; Isabelle Mahé
Journal:  Eur J Clin Pharmacol       Date:  2010-12-30       Impact factor: 2.953

3.  Home management of oral anticoagulation via telemedicine versus conventional hospital-based treatment.

Authors:  Henry Christensen; Jens-Jacob Lauterlein; Patricia D Sørensen; Eva R B Petersen; Jonna S Madsen; Ivan Brandslund
Journal:  Telemed J E Health       Date:  2011-01-23       Impact factor: 3.536

4.  Paracetamol: a haemorrhagic risk factor in patients on warfarin.

Authors:  I Mahé; N Bertrand; L Drouet; G Simoneau; E Mazoyer; C Bal dit Sollier; C Caulin; J F Bergmann
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

5.  Evaluation of the Steelex M600H coagulometer prothrombin time-international normalized ratio assay with Steelex test reagents.

Authors:  Yasemin U Budak; Kağan Huysal; Murat Polat; Gülsevil Tarakçi; Hakan Uçar
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

6.  New Approach for Interpreting Changes in Circulating Tumour Cells (CTC) for Evaluation of Treatment Effect in Metastatic Breast Cancer.

Authors:  Peer Horn; Erik Hugger Jakobsen; Jonna Skov Madsen; Ivan Brandslund
Journal:  Transl Oncol       Date:  2014-12       Impact factor: 4.243

7.  Monitoring of anticoagulant therapy in heart disease: considerations for the current assays.

Authors:  Mohammadali Boroumand; Hamidreza Goodarzynejad
Journal:  J Tehran Heart Cent       Date:  2010-05-31

8.  Long term monitoring in patients receiving treatment to lower blood pressure: analysis of data from placebo controlled randomised controlled trial.

Authors:  Katherine Keenan; Andrew Hayen; Bruce C Neal; Les Irwig
Journal:  BMJ       Date:  2009-04-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.